Life Sciences Transformational R&D Investment Fund (TRIF) Pilot

Funding
£5,000,000 – £25,000,000
Deadline
31 March 2030
Location
UK-wide
Applications
Deadline: 31 March 2030

Overview

The Life Sciences Transformational R&D Investment Fund (TRIF) Pilot is a £50 million capital grant fund from the Department for Science, Innovation and Technology. It supports large-scale R&D investments in the UK life sciences sector that focus on innovation and strengthening health resilience, with priority for projects that could generate economic benefits.

Applicants must be UK-registered, wholly private sector businesses operating as a product developer, contract development and manufacturing organisation (CDMO) or generics manufacturer, with a track record of developing or manufacturing medicines or medical devices. Projects must be located in the UK, be primarily a capital investment by a single company, cost at least £100 million in total and depend on the grant to proceed. Eligible R&D areas are human medicines, medical diagnostics and MedTech products.

Grants are set at the minimum level needed for the project to proceed, typically 10 to 20% of total project costs. Awards are capped at £25 million.

Applications run on a rolling basis until 31 March 2030, or until all the funding has been allocated. The process starts with an online expression of interest form through the Find a grant portal, followed by Application Form 1, a panel interview, Application Form 2 and due diligence. Questions can be emailed to TRIF@officeforlifesciences.gov.uk.

Official source: https://www.find-government-grants.service.gov.uk/grants/life-sciences-transformational-rd-investment-fund-trif-pilot-1. Last checked by GrantMatch on 16 November 2026.

Requirements to check

Key requirements:

  • Project must exceed £100 million in total costs

The company must be a UK-registered, wholly private sector business operating as a product developer, contract development and manufacturing organisation (CDMO) or generics manufacturer. It must provide two years of audited accounts for the applicant company or parent entity, or otherwise demonstrate that the remaining project funding has been secured. It must also show a track record of successfully developing or manufacturing medicines or medical devices, in the UK or internationally. The project must have a total cost of at least £100 million (including eligible capital and non-capital costs), be located in the UK, be primarily a capital investment, and be a single company investment rather than a partnership. It must depend on the grant to proceed: projects that would not occur, would be delayed by three years or more, would be scaled down, or would be relocated overseas without the grant may be eligible. Projects must involve R&D in human medicines (including active pharmaceutical ingredients and finished drug products), medical diagnostics or MedTech products. Not eligible: veterinary medicines, herbal medicines, nutritional supplements or vitamins, raw ingredients (e.g. solvents, buffers and cleaning agents), single-use consumables not integrated into a larger product, and secondary packaging. The scheme is UK-wide. Applications in scope of the Windsor Framework, for example projects located in Northern Ireland, are subject to European Commission State aid rules. Other applications fall under the Subsidy Control Act 2022. Funds can be recovered if subsidy control requirements are not met.

This summary may not include every exclusion. Check the full eligibility rules, including who and what the funder will not support.

See how well this grant fits your organisation, free

Create a free account and check your organisation against this grant’s requirements before you spend time applying. No card needed.

Start free

Who is this for?

This grant is for large life sciences companies and organisations planning major R&D projects. Your project must cost more than £100 million in total. It is suitable for manufacturing and health sector businesses working on innovation or health resilience projects.

Funder track record
Last published award 2025Open to first-time applicants

Awards published

30,043

Typical award

£62,476

Most awards

£25,530 to £143,021

Most funded region

London

53 awards in 2025, down from 6,337 the year before.

Recent awards include University of Manchester (£160,000, 2025), University of Sheffield (£160,000, 2025) and University of Wolverhampton (£160,000, 2025).

Contains data from 360Giving publishers, used under open licence.

Full details from Department for Science, Innovation and Technology

The Life Sciences Transformational R&D Investment Fund Pilot offers capital grants to support large-scale R&D projects in the UK life sciences sector (eligible projects must exceed £100 million in total costs). It aims to boost research and development within the UK's Life Sciences sector by supporting large-scale investments focused on innovation and strengthening health resilience, as well as projects with the potential to generate economic benefits. This fund complements the separate Life Sciences Innovative Manufacturing Fund (LSIMF).

How to apply

Start by completing the online expression of interest form through the GOV.UK Find a grant portal. If you meet the eligibility criteria you will receive an email, and a guidance session may be scheduled if helpful. You will then be asked to submit Application Form 1, the formal expression of interest, which is used to check eligibility and fit with the fund's objectives. Eligible projects are invited to the next stage by email. The health resilience and innovation benefits described in Application Form 1 are assessed by a panel of cross-government officials. This is followed by an interview with a panel of independent experts, which includes a 10-minute presentation and a short question-and-answer session. Panel interviews take place monthly. Successful applicants are then invited to complete Application Form 2, covering eligibility, company and project details, financial information, markets, economic impacts and project risks, with supporting documentation. Due diligence then assesses value for money, subsidy control compatibility, what would happen without the grant, deliverability, employment outputs and your ability to finance the project. DSIT reserves the right to offer less than the amount requested. Questions can be emailed to TRIF@officeforlifesciences.gov.uk.

Loading your grant tools...

Get notified about grants like this

Create a free account to receive alerts when new health & social work funding opens.

Create free account

Last updated: 16 November 2026